| Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis JA Cohen, F Barkhof, G Comi, HP Hartung, BO Khatri, X Montalban, ... New England Journal of Medicine 362 (5), 402-415, 2010 | 2802 | 2010 |
| Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor V Rothhammer, ID Mascanfroni, L Bunse, MC Takenaka, JE Kenison, ... Nature medicine 22 (6), 586-597, 2016 | 1170 | 2016 |
| Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ... Jama 321 (2), 175-187, 2019 | 461 | 2019 |
| Defining secondary progressive multiple sclerosis J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ... Brain 139 (9), 2395-2405, 2016 | 392 | 2016 |
| Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study A He, B Merkel, JWL Brown, LZ Ryerson, I Kister, CB Malpas, S Sharmin, ... The Lancet Neurology 19 (4), 307-316, 2020 | 290 | 2020 |
| Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis FJ Quintana, MF Farez, V Viglietta, AH Iglesias, Y Merbl, G Izquierdo, ... Proceedings of the National Academy of Sciences 105 (48), 18889-18894, 2008 | 276 | 2008 |
| Geographical variations in sex ratio trends over time in multiple sclerosis M Trojano, G Lucchese, G Graziano, BV Taylor, S Simpson Jr, V Lepore, ... PloS one 7 (10), e48078, 2012 | 261 | 2012 |
| Toll-like receptor 2 and poly (ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE MF Farez, FJ Quintana, R Gandhi, G Izquierdo, M Lucas, HL Weiner Nature immunology 10 (9), 958-964, 2009 | 224 | 2009 |
| MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis H Butzkueven, J Chapman, E Cristiano, F Grand’Maison, M Hoffmann, ... Multiple Sclerosis Journal 12 (6), 769-774, 2006 | 221 | 2006 |
| Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis VG Jokubaitis, T Spelman, T Kalincik, J Lorscheider, E Havrdova, ... Annals of neurology 80 (1), 89-100, 2016 | 206 | 2016 |
| Predictors and dynamics of postpartum relapses in women with multiple sclerosis SE Hughes, T Spelman, OM Gray, C Boz, M Trojano, A Lugaresi, ... Multiple Sclerosis Journal 20 (6), 739-746, 2014 | 204 | 2014 |
| Defining reliable disability outcomes in multiple sclerosis T Kalincik, G Cutter, T Spelman, V Jokubaitis, E Havrdova, D Horakova, ... Brain 138 (11), 3287-3298, 2015 | 201 | 2015 |
| Sex as a determinant of relapse incidence and progressive course of multiple sclerosis T Kalincik, V Vivek, V Jokubaitis, J Lechner-Scott, M Trojano, G Izquierdo, ... Brain 136 (12), 3609-3617, 2013 | 195 | 2013 |
| Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS KA Ribbons, P McElduff, C Boz, M Trojano, G Izquierdo, P Duquette, ... PloS one 10 (6), e0122686, 2015 | 192 | 2015 |
| Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ... Annals of Neurology 77 (3), 425-435, 2015 | 186 | 2015 |
| Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations G Kristjansdottir, JK Sandling, A Bonetti, IM Roos, L Milani, C Wang, ... Journal of medical genetics 45 (6), 362-369, 2008 | 174 | 2008 |
| Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, ... The Lancet Neurology 16 (4), 271-281, 2017 | 171 | 2017 |
| Multiple Sclerosis Risk Variant HLA-DRB1*1501 Associates with High Expression of DRB1 Gene in Different Human Populations A Alcina, MM Abad-Grau, M Fedetz, G Izquierdo, M Lucas, O Fernandez, ... PloS one 7 (1), e29819, 2012 | 168 | 2012 |
| Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis L Kappos, M Mehling, R Arroyo, G Izquierdo, K Selmaj, V Curovic-Perisic, ... Neurology 84 (9), 872-879, 2015 | 167 | 2015 |
| Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial D Cadavid, M Mellion, R Hupperts, KR Edwards, PA Calabresi, J Drulović, ... The Lancet Neurology 18 (9), 845-856, 2019 | 156 | 2019 |
